GSA Capital Partners LLP Invests $277,000 in Structure Therapeutics Inc. Sponsored ADR $GPCR

GSA Capital Partners LLP bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 9,886 shares of the company’s stock, valued at approximately $277,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Ameriprise Financial Inc. boosted its holdings in Structure Therapeutics by 7.2% during the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after purchasing an additional 106,389 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of Structure Therapeutics by 49.5% during the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares during the period. Pacific Heights Asset Management LLC boosted its stake in Structure Therapeutics by 52.2% in the 3rd quarter. Pacific Heights Asset Management LLC now owns 700,000 shares of the company’s stock valued at $19,600,000 after buying an additional 240,000 shares in the last quarter. Aberdeen Group plc grew its position in Structure Therapeutics by 46.1% in the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after acquiring an additional 185,245 shares during the period. Finally, Invesco Ltd. raised its stake in Structure Therapeutics by 7.6% during the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on GPCR shares. Citizens Jmp reduced their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research note on Friday. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Wall Street Zen raised shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, Guggenheim increased their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $105.50.

Structure Therapeutics Trading Down 2.7%

Shares of NASDAQ GPCR opened at $62.98 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $94.90. The company has a 50-day moving average of $75.41 and a two-hundred day moving average of $46.54. The company has a market cap of $4.45 billion, a PE ratio of -79.72 and a beta of -2.06.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.